NovoCure Analysts Boost Q1 Earnings Forecast

HC Wainwright raises estimates for the medical device company's first quarter results.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Stock analysts at HC Wainwright have increased their Q1 2026 earnings per share (EPS) estimates for NovoCure Limited (NASDAQ:NVCR), a global oncology company pioneering Tumor Treating Fields (TTFields) therapy. The analysts now anticipate NovoCure will post earnings of ($0.36) per share for the quarter, up from their prior estimate of ($0.54).

Why it matters

NovoCure's TTFields therapy is a novel anti-mitotic treatment for solid tumors, offering an alternative modality to complement existing cancer therapies. Positive earnings forecasts from analysts suggest growing confidence in the company's ability to commercialize this innovative technology.

The details

HC Wainwright analyst E. Bodnar raised the firm's Q1 2026 EPS estimate for NovoCure from ($0.54) to ($0.36). The analysts also issued updated estimates for NovoCure's full-year and future year earnings. For the current fiscal year, the consensus estimate is ($1.30) EPS. HC Wainwright has a 'Buy' rating and a $49.00 price target on NovoCure's stock.

  • NovoCure reported its Q4 2025 earnings on February 26, 2026.

The players

HC Wainwright

A stock research and investment banking firm that covers NovoCure.

E. Bodnar

An analyst at HC Wainwright who covers NovoCure.

NovoCure Limited

A global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Positive earnings forecasts from analysts suggest growing confidence in NovoCure's ability to commercialize its innovative Tumor Treating Fields therapy, which offers an alternative modality to complement existing cancer treatments.